Luca Licata, Medical Oncologist at San Raffaele Hospital, shared on X:
“Our review on the challenges and evidence gaps in treating premenopausal women with HR+/HER2- early breast cancer is now officially published in Annals of Oncology.
Many thanks again to all co-authors for this collaborative effort!”
Previously he also posted:
“HR+/HER2- early breast cancer in young women: evidence is growing, but many treatment decisions remain uncertain. In our new Annals of Oncology review, we provide a pragmatic framework to navigate these grey areas-highlighting what we know and what we still don’t know. A few key questions below.
Ovarian function suppression: who really needs it?
OFS improves outcomes, particularly in higher-risk disease, but comes with substantial toxicity. The challenge is how to tailor its intensity and duration to individual recurrence risk and patient priorities.
Chemotherapy benefit in premenopausal women: cytotoxic effect or ovarian suppression?
TAILORx, RxPONDER & MINDACT showed an apparent benefit-but how much reflects OFS? Several lines of evidence, now including OPTIMA, support an important chemo-endocrine effect.
Who should receive extended ET? For how long? And with which strategy?
Evidence specifically addressing women who remain premenopausal after 5 years is limited, making individual risk assessment and treatment tolerability critical.
How can we optimize treatment without overlooking its long-term impact?
Years of estrogen deprivation can affect QoL, adherence, sexual health, cognition and bone health, while treatment intersects with fertility and pregnancy. Balancing efficacy, burden & patient priorities is key.
This review was a truly international collaborative effort, and I’m grateful to an amazing team of co-authors for their expertise, thoughtful discussions, and contributions throughout the development of this work.”
Title: Navigating uncertainties and evidence gaps in adjuvant therapy for premenopausal women with HR-positive/HER2-negative breast cancer.
Authors: L. Licata, M. Mariani, A Chiavassa, A.H. Partridge, C. Zanibelli, K. Jhaveri, K. Kalinsky, F. Patanè, C. Criscitiello, M. Lambertini, H.S. Rugo, M.M. Naldini, G. Notini, G. Viale, L. Pusztai, G. Bianchini.
You can also read: Premenopausal HR+/HER2- Early Breast Cancer: Moving Beyond One-Size-Fits-All Adjuvant Therapy.
